Program
remestemcel-l
Also written as “Prochymal®”, “Remestemcel-L-rknd” and “PROCHYMAL®”.
Its studies are mostly in Graft vs Host Disease · Crohn Disease · Diabetes Mellitus, Type 1 · Pulmonary Disease, Chronic Obstructive · Myocardial Infarction, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mesoblast | 131 open or running | phase 3since Aug 17, 2006 | Aug 25, 2005 | Feb 28, 2028phase 3 · NCT07568535 |
| EHL Bio | 10 open or running | phase 1since Aug 15, 2016 | Aug 15, 2016 | none ahead |
Also a collaborator on its studies: quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 25, 2005First study: phase 2 study in Graft vs Host DiseaseNew to MesoblastMesoblast · NCT00136903 · 32 enrolled · United States
- Jan 31, 2006Phase 2 study in Graft vs Host DiseaseMesoblast · NCT00284986 · 11 enrolled · United States
- Feb 17, 2006Phase 2 study in Crohn DiseaseMesoblast · NCT00294112 · 10 enrolled · United States
- Aug 17, 2006Phase 3 study in Graft vs Host DiseaseMesoblast · NCT00366145 · 260 enrolled · United States, Australia, Canada and more
- May 30, 2007Phase 3 study in Crohn DiseaseMesoblast · NCT00482092 · 330 enrolled · United States, Australia, Canada and more
- Nov 20, 2007Phase 3 study in Graft vs Host DiseaseMesoblast · NCT00562497 · 192 enrolled · United States, Australia, Canada
- May 21, 2008Phase 2 study in Pulmonary Disease, Chronic ObstructiveMesoblast · NCT00683722 · 62 enrolled · United States
- Jun 2, 2008Phase 2 study in Diabetes Mellitus, Type 1Mesoblast · NCT00690066 · 63 enrolled · United States
- Apr 7, 2009Phase 2 study in Myocardial InfarctionMesoblast · NCT00877903 · 220 enrolled · United States, Canada
- Nov 2, 2010Phase 3 study in Crohn DiseaseMesoblast · NCT01233960 · 73 enrolled · United States, Australia, New Zealand
- Dec 30, 2014Phase 3 study in Grade B aGVHDMesoblast · NCT02336230 · 55 enrolled · United States
- Nov 3, 2015Phase 3 study in Grade B Acute Graft Versus Host DiseaseMesoblast · NCT02652130 · 32 enrolled · United States
- Aug 15, 2016EHL Bio's first study: phase 1 study in Dermatitis, AtopicNew to EHL BioEHL Bio · NCT02888704 · 13 enrolled · Korea, Republic of
- Apr 28, 2026Phase 3 study in Graft vs Host DiseaseMesoblast · NCT07568535 · 180 planned
Ahead
- Feb 28, 2028Primary completion: phase 3 study in Graft vs Host DiseaseMesoblast · NCT07568535
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07568535Graft vs Host Disease | 3 | Not yet recruiting | Mesoblast | Feb 28, 2028 | 180 |
| NCT02888704Dermatitis, Atopic · Korea, Republic of | 1 | Completed | EHL Bio | Dec 2017 | 13 |
| NCT02652130Grade B Acute Graft Versus Host Disease · United States | 3 | Completed | Mesoblast | Jun 15, 2018 | 32 |
| NCT02336230Grade B aGVHD · United States | 3 | Completed | Mesoblast | Apr 9, 2018 | 55 |
| NCT01233960Crohn Disease · United States, Australia, New Zealand | 3 | Completed | Mesoblast | Sep 15, 2014 | 73 |
| NCT00877903Myocardial Infarction · United States, Canada | 2 | Completed | Mesoblast | May 18, 2011 | 220 |
| NCT00690066Diabetes Mellitus, Type 1 · United States | 2 | Completed | Mesoblast | Dec 12, 2010 | 63 |
| NCT00683722Pulmonary Disease, Chronic Obstructive · United States | 2 | Completed | Mesoblast | Mar 9, 2009 | 62 |
| NCT00562497Graft vs Host Disease · United States, Australia, Canada | 3 | Completed | Mesoblast | Jul 14, 2009 | 192 |
| NCT00482092Crohn Disease · United States, Australia, Canada and more | 3 | Completed | Mesoblast | Sep 15, 2014 | 330 |
| NCT00366145Graft vs Host Disease · United States, Australia, Canada and more | 3 | Completed | Mesoblast | Dec 26, 2008 | 260 |
| NCT00294112Crohn Disease · United States | 2 | Completed | Mesoblast | Jul 21, 2006 | 10 |
| NCT00284986Graft vs Host Disease · United States | 2 | Completed | Mesoblast | Apr 25, 2006 | 11 |
| NCT00136903Graft vs Host Disease · United States | 2 | Completed | Mesoblast | Jul 28, 2006 | 32 |
How it is read
Names in the registry
- “Prochymal®”, 5 entries
- “Remestemcel-L-rknd”, 1 entry
- “PROCHYMAL®”, 1 entry
- “Prochymal™”, 1 entry
- “Prochymal”, 1 entry
Conditions, from the studies’ own filings
- Graft vs Host Disease, 6 studies
- Crohn Disease, 3 studies
- Diabetes Mellitus, Type 1, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
- Myocardial Infarction, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.